Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
Patients with HIV-1 infection on HAART regimen including 2 NRTI/NtRTIs plus one of the following : 1 PI/ritonavir or ATV/unboosted or 1 NNRTI, will be randomized to switch from the NNRTI/PI to maraviroc (300 mg /12 h) or to continue with the same approach.
Epistemonikos ID: 6aab16c14a58796b7528b36a43f517a2915bc548
First added on: Dec 01, 2021